News

Replimune stock plunges after FDA rejects melanoma treatment application
Investing.com -- Replimune Group, Inc. (NASDAQ: REPL) stock plunged 77% after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) ...
Investor's Business Daily on MSN6d
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma ...
Replimune plunges as FDA rejects its lead drug for skin cancer
Replimune (REPL) stock in focus as the FDA rejects its lead drug RP1 as part of a combination regimen for melanoma, a type of ...
PharmExec4d
Replimune CRL Fallout: How Biopharma Leaders Should Manage a New Layer of FDA Uncertainty
A deep dive into the implications of the Replimune CRL that surprised insiders and investors, the role of new leadership at ...
Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment
Replimune said the agency had issued a complete response letter regarding the company’s biologics license application for RP1 ...
The Bakersfield Californian19h
Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection ...
A securities class action lawsuit, styled Jboor v. Replimune Group, Inc., et al., No. 1:25-cv-12085 (D. Mass.), has been filed and seeks ...
FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks
Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.